Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via...

Area of Science:

• Pharmacology
• Drug Delivery
• Biochemistry

Background:

• Berberine's clinical use for diabetes is limited by poor oral bioavailability.
• Low solubility and membrane permeability hinder berberine absorption.
• Developing strategies to improve berberine's oral delivery is crucial.

Purpose of the Study:

• To develop and characterize an amorphous solid dispersion of berberine with sodium caprate (HGSD).
• To evaluate the enhanced dissolution, oral bioavailability, and anti-diabetic effects of HGSD.
• To investigate the potential of HGSD as an improved therapeutic agent for diabetes.

Main Methods:

• Amorphous solid dispersions (HGSDs) prepared by solvent evaporation.
• Characterization using X-ray diffraction, DSC, and SEM.
• In vitro, in situ, and in vivo pharmacokinetic evaluations in rats.
• Assessment of anti-diabetic effects in a type 2 diabetic rat model.

Main Results:

• HGSD formulations, particularly P9, showed berberine in an amorphous form with significantly increased solubility and dissolution.
• P9 demonstrated a 3-fold increase in in vitro permeation, 4-fold in situ intestinal perfusion, and 5-fold in vivo bioavailability.
• Oral administration of P9 improved glucose and lipid metabolism in diabetic rats.

Conclusions:

• HGSD significantly enhances berberine's oral bioavailability and therapeutic efficacy.
• P9 represents a promising drug candidate for diabetes treatment.
• Amorphous solid dispersion technology offers a viable approach to overcome berberine's pharmacokinetic limitations.